Navigation Links
Surface Logix Announces Executive Management Changes
Date:5/15/2008

BOSTON, May 15 /PRNewswire/ -- Surface Logix today announced that Jim Mahoney, President & CEO, will be stepping down from his current position to pursue other interests. Mr. Mahoney will maintain a consulting relationship with the company for the foreseeable future. Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners will assume the role of Executive Chairman until a new CEO is appointed.

"The Board, shareholders and employees of Surface Logix would like to thank Jim for his considerable contributions to the Company. He led the transformation of Surface Logix from a chemistry platform to a small molecule drug discovery and development company with two internally generated programs having completed several successful Phase 2a clinical trials. Everyone at Surface Logix wishes Jim well in his decision to pursue other interests," said Steven Gillis. "Surface Logix is well positioned to move forward both of our cardiovascular programs, SLx-4090 and SLx-2101, into Phase 2b studies. Both programs have demonstrated clear efficacy and excellent tolerability and safety in clinical trials to date. We will also continue our research activities aimed at bringing exciting new programs to the clinic."

About Surface Logix, Inc.

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, oncologic and fibrotic diseases. For more information, please visit http://www.surfacelogix.com .

Contact:

Leland Webster, Ph.D., M.B.A.

Surface Logix, Inc.

Vice President, Corporate Development

617.746.8520

Media:

Kari Watson

MacDougall Biomedical Communications Inc.


SOURCE Surface Logix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Surface dislocation nucleation: Strength is but skin deep at the nanoscale, Penn engineers discover
2. CaviWipes(R): Taking Surface Disinfection to a New Level
3. Arthrosurface Raises $4 Million of Preferred Equity Financing
4. Harland Medical Systems to Offer March Plasma Systems Surface Materials
5. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
6. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
7. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
8. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
9. Physicists pin down spin of surface atoms
10. /C O R R E C T I O N from Source -- Resverlogix Corp./
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Aug. 7 SyntheMed, Inc. (OTC Bulletin Board: SYMD), ... of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion ... National Association for Children,s Heart Disorders, Inc. Michelle L. ... to inform parents of children with congenital heart defects ...
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation today ... distribution rights, along with the trademark, inventory and other ... line. Under the terms of the agreement, the Company ... OsseoFit distribution agreement. Pursuant to the agreement, following a ...
Cached Biology Technology:REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... inexpensive land along coastlines for vacation homes and tourist hotels. ... that threatens the very coral reefs attracting tourists in the ... Research Institute and colleagues find that bacteria on coral reefs ... in seawater increases. , "I set up a seawater system ...
... Garvan Institute, in collaboration with Spanish scientists, have formulated ... normal growth controls, which may have far-reaching implications for ... found large regions of DNA are 'switched off' in ... the Garvan Institute, says: "These large regions ?referred to ...
... multifaceted study involving the Kuna Indians of Panama, ... chemical compound that is, in part, responsible, for ... chocolate products. , The researchers, who are from ... of Duesseldorf, Germany; and Harvard Medical School, hope ...
Cached Biology News:Cancer cells suppress large regions of DNA by a reversible process that can be tackled 2Heart-healthy compound in chocolate identified 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Materials for 15-20 enhancements when used as directed, ... Enhancement System is designed to amplify the desired signal ... for evaluating proteins with low expression., ... to blocking the membrane; 1x solution; 250 ml, ...
Applications: Western blotting ...
Biology Products: